Two studies explore molecular divergence in gastric cancer
Genomic landscaping suggests molecular divergence between cancer subtypes and across disease stages, but molecular similarities between White and Asian populations
Women receiving immunotherapy may be at higher risk of adverse events than men
Prospective evidence from a multicentre study support the need for a more personalised immuno-oncology approach based on sex and gender differences
Bexmarilimab monotherapy shows promising anti-tumour activity in advanced solid tumours
Preliminary data indicate tolerability and disease control with bexmarilimab in hard-to-treat solid tumours
PARP inhibitor re-treatment: the future of maintenance therapy for relapsed ovarian cancer?
A significant progression-free survival improvement after re-treatment with olaparib was reported in the OReO/ENGOT Ov-38 trial
Early and relapsed TNBC is no longer so negative
Research and treatment approaches have come a long way since triple-negative breast cancer was first recognised, but there is still progress to be made, according to Associate Prof. Rebecca Dent
What to expect from ESMO 2021?
We were hoping to be in Paris for the ESMO Congress 2021, but the event will be virtual for the second consecutive year due to the COVID-19 pandemic. However, this annual Congress will confirm that cancer research is blooming again, despite the current health crisis and its remarkable consequences on people, healthcare system, and, not the least, research
From empiric testing to rational design: two decades of progress in phase I trials
Ensuring equitable access to innovative treatments is now the major challenge in oncology, says Prof. Alex Adjei
Translating research ideas into patient benefits
Investigations are time-consuming and expensive, so greater public funding is needed, according to Prof. George Coukos
